Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24635959 | 0.71 | — | — | |
| SCHEMBL8744503 | 0.71 | — | — | |
| SCHEMBL3730185 | 0.71 | — | — | |
| SCHEMBL38652945 | 0.71 | — | — | |
| SCHEMBL6658492 | 0.69 | — | — | |
| SCHEMBL8332155 | 0.67 | — | — | |
| SCHEMBL12160740 | 0.67 | — | — | |
| SCHEMBL357257 | 0.67 | — | — | |
| SCHEMBL18289456 | 0.67 | ITGB1 (0.40) | MAP3K14ITGB3ITGB2ITGB1ITGAV | |
| SCHEMBL19047109 | 0.67 | MAP3K14 (0.60) | MAP3K14CRBNBRD4CREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11787968-B2 | Coating composition | PPG INDUSTRIES OHIO, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230314945-A1 | NEGATIVE-TONE RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230295096-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11708444-B2 | Acrylic polyester resin and an aqueous coating composition containing the same | PPG INDUSTRIES OHIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-7442687-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008110774-A2 | PENTALENES | ISIS INNOVATION LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |
| US-20080194741-A1 | Flowable Thermoplastic Materials With Halogen-Free Flame Protection | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008079383-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-7241551-B2 | Positive-working resist composition | FUJIFILM CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7241551-B2 | Positive-working resist composition | FUJIFILM CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20070082187-A1 | Celluosic products comprising substantially voc-free compositions | CHEMCO, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7169838-B2 | Halogen-free flameproof polyester | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-30 | — | — | US | disclosed |
| US-4958022-A | Polycyclic compounds | BASF AKTIENGESELLSCHAFT (DE) | 1990-09-18 | — | — | US | disclosed |
| EP-0330131-A1 | Polycyclic compounds and their use | BASF Aktiengesellschaft (DE) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | MAP3K14 3768/4885ITGB3 3950/4885ITGB2 3978/4885 |
| US-20230295096-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | MAP3K14 3300/4885ITGB3 3765/4885ITGB2 4172/4885 |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | MAP3K14 760/4885ITGB3 3339/4885ITGB2 3517/4885 |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | MAP3K14 3768/4885ITGB3 3950/4885ITGB2 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.